The verdict
Our read at a glance.
Whether caspofungin is understood as an approved antifungal for specific invasive fungal infections (Candida, salvage Aspergillus, empirical neutropenic fever), rather than a general antifungal or a stand-in for unproven antimicrobial-peptide claims.
- The signal
- Trials show caspofungin works at least as well as older antifungals like amphotericin B and fluconazole for invasive Candida infections, with fewer side effects, which is why echinocandins are now a first-line choice for invasive candidiasis; for invasive aspergillosis it is used mainly as a backup option.
- The unknown
- Its best role versus the other echinocandins and azoles, combination strategies in tough infections, and emerging echinocandin resistance in some Candida species.
- Our read
- A well-tolerated, approved antifungal peptide that reliably treats serious invasive Candida infections and serves as backup for invasive aspergillosis. Its fungal-cell-wall target makes it gentle on people, and it is now first-line for invasive candidiasis, another concrete example of an approved antimicrobial peptide, not a general or topical antifungal.
The mechanism
How it works.
Fungal cells, unlike human cells, build their outer wall partly from a mesh of sugar chains called beta-glucan. Caspofungin is a ring-shaped peptide with a fatty tail that blocks the enzyme fungi use to make beta-glucan. Without enough beta-glucan, the fungal cell wall weakens and the cell bursts under its own internal pressure. Because human cells have no such wall and no beta-glucan, the drug attacks the fungus while largely sparing the patient, which is why it is gentler than older antifungals. It is given by vein for invasive infections, mainly those caused by Candida.
Safety & regulatory boundary
The consequential part.
Caspofungin is generally well tolerated because its target, the fungal cell wall, does not exist in human cells; the main issues are occasional infusion (histamine-type) reactions, liver-enzyme changes, low potassium, and some drug interactions. It is an IV hospital antifungal for specific invasive fungal infections, not a treatment for ordinary superficial fungal infections, and the echinocandins (caspofungin, micafungin, anidulafungin) are a related but distinct class.
What's next
What we're watching.
Comparative data among echinocandins and against azoles, the spread of echinocandin-resistant Candida (including C. auris), and combination approaches.
Context
Why this is discussed.
Caspofungin is another real, approved antimicrobial peptide, an antifungal this time. It matters because it treats dangerous invasive fungal infections, especially Candida in the bloodstream, and is much gentler than the older drug amphotericin B.
The evidence base
14 cited references.
Regulatory & labels3
Sagent Pharmaceuticals (FDA label) · 2023
Gland Pharma Limited (FDA label) · 2022
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (FDA label) · 2025
Registered trials2
ClinicalTrials.gov · PHASE2/PHASE3 · COMPLETED · 2009-02
ClinicalTrials.gov · RECRUITING · 2022-10-01
Indexed literature (PubMed)9
Thompson GR et al. · Clin Infect Dis · 2021
Kullberg BJ et al. · Clin Infect Dis · 2019
Parakh A et al. · Indian Pediatr · 2008
Thompson GR 3rd et al. · Lancet Infect Dis · 2024
Cappelletty D et al. · Pharmacotherapy · 2007
Denning DW · Lancet · 2003
Keating GM et al. · Drugs · 2001
Honoré PM et al. · Crit Care · 2024
Erdem H et al. · Antimicrob Agents Chemother · 2025
Keep reading